Cytek Biosciences, Inc. (CTKB) Fair Value 2026

CTKB · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.9 /10

32 fundamental signals · 3 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-27, Cytek Biosciences, Inc. (CTKB) trades at $4.62, versus a $2.10 median fair value across its 3 active models — 54.5% below the current price. QOC: 6.9/10. Value Trap Risk: 26/100 (LOW). 3/13 models active.

Key Facts

Ticker
CTKB
Price
$4.62
Quality Score
6.9/10
Value Trap Risk
26/100
Models Active
3/13
Last Updated
Strength: 3 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Cytek Biosciences, Inc. (CTKB) Undervalued or Overvalued in 2026?

According to CirclFi’s 3-model valuation engine, Cytek Biosciences, Inc. (CTKB) appears overvalued as of : the median of 3 independent fair value estimates is $2.10, 54.5% below the current price of $4.62. Estimates range from $1.23 to $4.18. CTKB scores 6.9/10 on fundamental quality and 26/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. CTKB’s -54.5% gap is wider than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Cytek Biosciences, Inc. Stock in 2026? →

What Fair Value Does Each Model Give CTKB?

3 Intrinsic Value Models vs. Current Price ($4.62)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $1.23 -73.4%
Relative · Medium Conviction
 $2.10 -54.5%
Relative · Low Conviction
 $4.18 -9.5%

All Models Active

All 3 models are displayed above.

What Is CTKB's Fair Value Range?

Spread across 3 independent models · $1.23 to $4.18

CirclFi's 3 active models place Cytek Biosciences, Inc. (CTKB) between $1.23 and $4.18 per share, a spread of 140% of the median. The median of that range — $2.10 — is the fair value CirclFi publishes for CTKB, against a current price of $4.62.

Low · Dynamic NAVHigh · FTNN
$1.23median $2.10$4.18
Where the range comes from
Most bearish modelDynamic NAV$1.23
Most bullish modelFTNN Topology$4.18
Model agreement0 bullish · 3 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for CTKB. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on CTKB, not a CirclFi price target. How each model works →

What Is Cytek Biosciences, Inc. (CTKB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Cytek Biosciences, Inc.'s intrinsic value is estimated at $2.10. Trading at its current price of $4.62, the valuation engine raises significant caution: 3 of 3 models flag downside risk, projecting a median implied return of -54.5%. Notably, FTNN sees the most upside at -9.5% (fair value: $4.18), while Dynamic NAV is the most conservative at -73.4% ($1.23). The spread between these extremes — +63.9% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About CTKB?

3 of 13 models are currently active for CTKB. All 3 active models suggest the stock trades above fair value. Taken together, their median fair value for CTKB is $2.10 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does CTKB Rank in Medical Devices?

Among 157 Medical Devices stocks, CTKB ranks #53 by Quality of Company score. CirclFi's QOC score of 6.9/10 evaluates 32 fundamental signals. A score of 6.9 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

Cytek Biosciences, Inc.'s positioning within the Medical Devices segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.

Is CTKB a Value Trap?

CirclFi's Value Trap algorithm assigns CTKB a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

3 of 13 models are active for Cytek Biosciences, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Cytek Biosciences, Inc. earns a quality score of 6.9/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +63.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CTKB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CTKB's 3 active models, average confidence is 35%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Cytek Biosciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

CERSCerus CorporationQOC 6.9ARAYAccuray IncorporatedQOC 6.9PRCTPROCEPT BioRobotics CorporationQOC 6.9ATECAlphatec Holdings, Inc.QOC 6.9MXCTMaxCyte, Inc.QOC 7.0NEOGNeogen CorporationQOC 6.9BTCYBiotricity, Inc.QOC 6.0RMSLREMSleep Holdings, Inc.QOC 4.6TCMDTactile Systems Technology, Inc.QOC 8.8IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: CERS · ARAY · PRCT · ATEC · MXCT · NEOG · BTCY · RMSL · TCMD · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to CTKB?

7 companies across all industries closest to CTKB’s Quality of Company score of 6.9/10.

CAVACAVA Group, Inc.QOC 6.9PCSVPCS Edventures!, Inc.QOC 6.9AEHRAehr Test Systems, Inc.QOC 6.9MQMarqeta, Inc.QOC 6.9EMLThe Eastern CompanyQOC 6.9HRIHerc Holdings Inc.QOC 6.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CAVA · PCSV · AEHR · MQ · EML · HRI · NVDA

Where Does CTKB Sit in CirclFi's Medical Devices Rankings?

CTKB is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Cytek Biosciences, Inc.’s Valuation?

What is Cytek Biosciences, Inc.'s intrinsic value in 2026?

CirclFi puts Cytek Biosciences, Inc. (CTKB)'s intrinsic value at $2.10 — the median of 3 independent model estimates as of 2026-08-27, ranging from $1.23 to $4.18. The Quality of Company score is 6.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CTKB overvalued or undervalued right now?

At $4.62, 0 of 3 active models suggest CTKB may be undervalued, while 3 indicate potential overvaluation. The median of all 3 fair value estimates is $2.10, 54.5% below the current price of $4.62 — a consensus view that CTKB is overvalued. The assessment depends on which methodology best fits Cytek Biosciences, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 6.9 mean for CTKB?

Cytek Biosciences, Inc.'s QOC of 6.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CTKB?

CirclFi analyzes CTKB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 3 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on CTKB?

Of the 3 models currently active on CTKB, FTNN Topology is the most bullish at $4.18 per share, and Dynamic NAV is the most bearish at $1.23. CirclFi's published fair value for CTKB is the median of that range, $2.10, not either extreme. The gap between the two ends equals 140% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is CTKB a value trap in 2026?

Cytek Biosciences, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 3-model valuation engine, Cytek Biosciences, Inc. (CTKB) has a median fair value of $2.10 — 54.5% below the current price of $4.62 — as of 2026-08-27.” Source: circlfi.com/stock/CTKB/ · Methodology
Primary sources for this CTKB valuation
  • Financial statements: Cytek Biosciences, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001831915) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CTKB as of ; valuations recomputed .